Micancer Center S.L.P.

The Micancer Center focuses on innovative treatments for well‑controlled recurrent pericarditis, aiming to improve long‑term disease management and reduce reliance on chronic therapies.

• Evaluation of KPL‑387 monotherapy transition regimens
• Long‑term efficacy and safety monitoring of pericarditis therapy
• Assessment of patient‑reported outcomes in cardiovascular trials

Research is conducted by a dedicated team of cardiology investigators within a European hospital setting.

Clinical research at the site targets non‑small cell lung cancer and related respiratory malignancies, testing new targeted agents and immunotherapy combinations to enhance survival.

• ROS1‑positive NSCLC selective inhibitor studies
• ALK‑positive NSCLC resistance mutation therapies
• Immunotherapy‑based combination regimens for metastatic lung cancer
• Intracranial response assessment in patients with brain metastases

Over twenty trials involve 13 investigators, reflecting a strong focus on advanced lung cancer care.

The center conducts oncology studies across a spectrum of solid tumors, including advanced breast cancer, head and neck squamous cell carcinoma, and melanoma, to compare novel agents with standard therapies.

• HER2‑low breast cancer T‑DXd versus CDK4/6 inhibitor plus endocrine therapy
• HPV‑negative head and neck cancer survival trial with ficlatuzumab plus cetuximab
• Biosimilar comparison of MB11 to Opdivo in untreated metastatic melanoma
• Combination strategies for advanced solid tumors using investigational antibodies

These studies aim to expand therapeutic options and improve overall survival for patients with aggressive cancers.

Supportive‑care research addresses complications of cancer treatment, such as chemotherapy‑induced thrombocytopenia, to maintain patients’ bone‑marrow health and treatment continuity.

• Hetrombopag pharmacokinetic profiling in non‑Asian participants
• Efficacy evaluation of hetrombopag for platelet recovery
• Safety monitoring of supportive agents during intensive chemotherapy

The work integrates hematologic expertise with oncology to reduce treatment‑related toxicity.

Advanced diagnostic and dosing studies are performed to refine therapeutic precision, including pharmacokinetic biosimilarity and biomarker‑driven patient selection.

• PK and bioequivalence assessment of MB11 versus Opdivo
• Biomarker‑guided enrollment for immunotherapy trials
• Dose‑optimization investigations for combination regimens
• Imaging and response criteria development for intracranial disease

These efforts support the development of safer, more effective treatment protocols across multiple disease areas.

A collaborative framework unites investigators from diverse specialties to address safety, efficacy, and quality‑of‑life outcomes across all therapeutic areas studied at the site.

• Integrated safety monitoring across oncology and cardiovascular trials
• Patient‑reported outcome collection for advanced cancer therapies
• Real‑world evidence integration from multiple disease cohorts
• Multi‑disciplinary investigator platform fostering cross‑area innovation

This holistic approach enhances translational impact and ensures comprehensive evaluation of new medical interventions.